From The Economic Times · PTI · · 50s
Dr Reddy's Gets DCGI Approval for Zytorvi
Dr Reddy's Laboratories receives DCGI nod for Zytorvi immunotherapy in advanced esophageal cancer.
In brief
Dr Reddy's Laboratories receives DCGI nod for Zytorvi immunotherapy in advanced esophageal cancer. Dr Reddy's Laboratories gained DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India. Originally reported by The Economic Times.
DCGI Approval for Zytorvi
Dr Reddy's Laboratories received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.
Second Approved Indication
Zytorvi is the second approved indication in India, expanding beyond nasopharyngeal carcinoma.
ESCC Accounts for 80% of Cases
Advanced esophageal squamous cell carcinoma accounts for approximately 80 per cent of all esophageal cancer cases in India.
Phase 3 Trial Results
The Phase 3 JUPITER-06 trial showed Zytorvi reduced disease or death risk by 42 per cent compared with chemotherapy alone.
The big picture
Dr Reddy's Laboratories gained DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.
